Manali Bhave

Assistant Professor

Winship Cancer Institute of Emory University
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (1)

Purpose: Imlunestrant is an oral selective estrogen receptor degrader with favorable safety and preliminary efficacy in patients with advanced breast cancer. Pharmacodynamic (PD) biomarker data can optimize drug dosing; in this study, we present PD data from the EMBER-2 study. Patients and Methods: Postmenopausal women with untreated, operable estrogen receptor (ER)–positive, HER2-negative early breast cancer were randomized to 400 versus 800 mg of imlunestrant daily for ∼2 weeks before surgery. A single arm study tested a daily dose of 200 mg. PD biomarker changes (ER, progesterone receptor, Ki-67 by IHC, and mRNA expression of ER-related genes) were evaluated in paired tumor samples (pre-/posttreatment). Safety and pharmacokinetics were also assessed. Results: Among evaluable paired samples ( n = 75), PD profiles demonstrated consistent ER targeting between 400- and 800-mg doses, with less toxicity at the 400-mg dose. Although inducing the lowest rate of complete cell-cycle arrest, PD and pharmacokinetic results were similar for the 200-mg dose. Conclusions: EMBER-2 combined with existing phase I data has identified 400 mg as the optimal imlunestrant dose.

Year:

2024

Collaborators (9)

Patrick Neven

University Hospitals Leuven

BELGIUM
View details

Francois-Clement Bidard

Professor of Medical Oncology

Institut Curie

FRANCE
View details

Nadia Harbeck

-

GERMANY
View details

Kelly K Hunt

Chair

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Peter Schmid

Professor of Cancer Medicine and Honorary Consultant in Medical Oncology, Centre Lead, Centre for Experimental Cancer Medicine

Barts Cancer Institute

UNITED KINGDOM
View details

Peter Fasching

-

GERMANY
View details

Swati Kulkarni

Professor of Surgery

Northwestern University

UNITED STATES
View details

Miguel Martin

Universidad Complutense de Madrid

SPAIN
View details

Eva M. Ciruelos-Gil

Universidad Complutense de Madrid

SPAIN
View details